Vienna, Sept. 8, 2010 – Vela
Laboratories, a provider of
analytical services to the global
biopharmaceutical industry, today
announced the renewal of the GMP
certificate for its analytical and
Quality Control laboratories until
2013.

“We are pleased that Vela
Laboratories has its GMP
certification renewed, as this
achievement will further strengthen
our position as a provider to the
global pharmaceutical and
biotechnology industry,” said Dr.
Markus Fido, co-founder and CEO of
Vela Laboratories. “Vela has
established a broad analytical
method portfolio, serving the needs
of manufacturers of
Biopharmaceuticals and Biosimilars
in Europe, North America, and
India, including the
characterization of complex
proteins like monoclonal antibodies
or growth factors.”

“The fact that no findings were
made during the inspection
demonstrates that our whole team is
dedicated to the highest quality
standards,” said Dr. Andreas
Nechansky, co-founder and COO of
Vela Laboratories. “The renewal of
the GMP certification for our
analytical and Quality Control
laboratories confirms that we are
on the right track towards our goal
of becoming a major player in the
analytical services business.”

‘Good Manufacturing Practice’ is a
body of internationally accepted
regulations set forth by EU and US
drug agencies. GMP compliance
ensures that pharmaceuticals,
active ingredients and medical
devices are produced and
quality-controlled according to
state-of-the-art standards. GMP
compliance is the gold standard in
quality for the life sciences industry.

About Vela Laboratories

Vela Laboratories (Vela
pharmazeutische Entwicklung und
Laboranalytik GmbH) provides a
broad portfolio of analytical
methods for the preclinical and
clinical development including
studies in support of regulatory
submissions and product release for
Biopharmaceuticals and Biosimilars,
including monoclonal antibodies and
growth factors.